

REVIEW
Cardiac Fibroblasts

Fibroblasts and immune cells: at the crossroad of organ inflammation and fibrosis

Sasha Smolgovsky,^{1,2} Brandon Theall,^{1,2} Noah Wagner,¹ and  Pilar Alcaide^{1,2}

¹Department of Immunology, Tufts University School of Medicine, Boston, Massachusetts, United States and ²Immunology Graduate Program, Graduate School of Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts, United States

Abstract

The immune and fibrotic responses have evolved to work in tandem to respond to pathogen clearance and promote tissue repair. However, excessive immune and fibrotic responses lead to chronic inflammation and fibrosis, respectively, both of which are key pathological drivers of organ pathophysiology. Fibroblasts and immune cells are central to these responses, and evidence of these two cell types communicating through soluble mediators or adopting functions from each other through direct contact is constantly emerging. Here, we review complex junctions of fibroblast-immune cell cross talk, such as immune cell modulation of fibroblast physiology and fibroblast acquisition of immune cell-like functions, as well as how these systems of communication contribute to organ pathophysiology. We review the concept of antigen presentation by fibroblasts among different organs with different regenerative capacities, and then focus on the inflammation-fibrosis axis in the heart in the complex syndrome of heart failure. We discuss the need to develop anti-inflammatory and antifibrotic therapies, so far unsuccessful to date, that target novel mechanisms that sit at the crossroads of the fibrotic and immune responses.

cardiovascular; fibroblasts; fibrosis; immune cells; inflammation

INTRODUCTION

Organ fibrosis is defined as the excessive deposition of extracellular matrix (ECM) proteins, a process which is advantageous in the short term. In cases of injury, fibrotic remodeling can act to promote tissue repair, as well as provide necessary structure to the damaged organ. In addition, fibrotic remodeling helps replace dead or infected cells. This process of replacement fibrosis often results in a fibrotic scar that repairs the site of injury. In contrast, fibrosis also occurs in the absence of cell loss because of alterations in the ECM, in what has been termed reactive fibrosis. In both cases, fibrosis leads to impaired organ physiology in the long term, and particularly in the heart, an organ with limited regenerative capacity, resulting in longstanding pathology and dysfunction contributing to the deadly syndrome of heart failure (HF). Immune cells are often found in fibrotic areas and can secrete profibrotic cytokines that alter the activity of fibroblasts, the major cells producing collagen and other components of the ECM, which adopt a profibrotic function in response to this interaction. Conversely, fibroblasts express immune pattern recognition receptors (PRRs), cytokine and chemokine receptors that allow them to adopt “immune-like” functions when engaged. These include the secretion of proinflammatory cytokines and

chemokines, which attract immune cells to the fibrotic site as part of the immune response as well as the expression of molecules involved in antigen presentation.

Here, we review recent discoveries of molecular players in immune cell-fibroblast cross talk. We comment on different cellular states of immune cells and fibroblasts adopting functions from each other during homeostasis and throughout the course of disease. We present recently discovered novel functions of fibroblasts as antigen-presenting cells in the joint, gut, tumors, and heart. In addition, we focus on fibroblast states and immune cell subsets that work in a network central to cardiac remodeling and have consequences in the different etiologies of the complex syndrome of HF. This review provides an opportunity to explore what may be therapeutically targeted at the interphase of fibroblasts and immune cell physiology to control organ inflammation and fibrosis.

IMMUNE CELL CONTRIBUTION TO TISSUE AND ORGAN FIBROSIS
Fibroblasts and Immune Cells in a Nutshell

Fibroblasts are responsible for providing organ rigidity and flexibility, an effect achieved by the deposition of ECM

proteins. They are highly plastic stromal cells that adopt different phenotypically distinct states in response to extracellular cues in their microenvironment. Transition between states often occurs in disease settings with defined temporal stages that align with immune cell infiltration. Although at least four fibroblast states have been identified in multiple organs, different insults and changes in the organ microenvironment can lead to more complex intermediate states, such as in response to myocardial ischemia, as previously reviewed (1, 2) (Fig. 1A).

In addition to ECM synthesis and growth factor secretion, fibroblasts can release chemokines and cytokines, effectively adopting immune-like functions (Fig. 1B), a process that has been reported in multiple organs, as well as in tumor-associated fibroblasts (3). Fibroblasts have also received recent attention as communication hubs within organs, showing a surprising breadth of interaction with other resident cells including epithelial cells, endothelial cells, cardiomyocytes, tumor cells, and immune cells (4, 5). Although the production of ECM, cytokines, and chemokines is common to all fibroblasts (6, 7), it is becoming evident that the heterogeneous

fibroblast origins and the high degree of fibroblast phenotypic plasticity can be imprinted by the tissue niche as an adaptive mechanism that helps with the mechanical and physiological needs of each organ to maintain homeostasis and respond to insults (8). These states are shaped by resident and infiltrating immune cells, which contribute to fibroblast cell plasticity and organ adaptation to stress.

Immune cells are generally categorized into two arms of immunity: innate and adaptive. Ongoing characterization of different immune cell phenotypic states has revealed that this categorization may not be so stringent, with some immune cell types sharing properties of both arms (9, 10). Broadly, innate immune cells include neutrophils, tissue-resident, and tissue-infiltrating macrophages, and dendritic cells (DCs), which present antigens to lymphocytes and initiate adaptive immune responses, and serve as the necessary link between innate and adaptive immunity. Macrophages constitute one of the most plastic immune cell types in the body, and they participate in phagocytosis of debris and secretion of cytokines that have effects on immune and organ stromal cells, including fibroblasts. A current simplistic




Figure 1. A: possible fibroblast phenotypic states. Resting fibroblasts (orange) play homeostatic roles through maintaining extracellular matrix (ECM) proteins. They are also key producers of colony-stimulating factor 1 (CSF1) and platelet-derived growth factors (PDGFs), as well as baseline production of interferons (IFNs) that function in homeostatic regulation. Myofibroblasts (brown) are highly proliferative and proinflammatory cells. They have an increased production of ECM and are largely responsible for the development of fibrosis across multiple organ systems and engage in immune cell recruitment through a variety of cytokines. Senescent fibroblasts (blue) are highly inflammatory nondividing fibroblasts, classically characterized by an upregulation in senescence-associated genes (SAGs) (such as β -galactosidase, β -Gal), which, when expressed, leads to the development of a senescence-associated secretory phenotype (SASP). Matrifibrocytes (red) are a recently described subpopulation of semisenescence fibroblasts. Their exact roles in immune cell recruitment, fibrotic development, and IFN production are currently subjects of study. While all well-defined states are listed here, depending on the disease setting and cues from the microenvironment, fibroblasts may transition between several or all of these phenotypes, and others not represented herein, such as in the case of myocardial ischemia. B: resting fibroblasts (orange) produce prosurvival signals like CSF1 and PDGF α to macrophages and other immune cells. These same immune cells also send prosurvival signals back to the fibroblast pool. Conversely, inflamed fibroblasts (brown) produce proinflammatory cytokines such as CCL2, IFN γ , and IFN β , which activate and recruit immune cells. They also self-signal through the production of transforming growth factor β (TGF- β) to encourage the transformation of surrounding fibroblasts. Immune cells (right) produce proinflammatory cytokines such as IL-1 α , IL-12, TGF- β , and osteopontin to further activate the inflammatory response in fibroblasts. C: fibroblasts are capable of immune cell recruitment. Resting fibroblasts (left) are activated by mechanical stresses or immune factors and begin producing proinflammatory and immune recruiting factors such as monocyte chemoattractant protein-1 (MCP-1)/CCL2, CXCL2, and IL-11, which signal on immune cells to migrate into sites of inflammation. In addition, fibroblasts communicate with tissue-resident macrophages. These events lead to the inflamed state of the tissue. D: T cells and fibroblasts interact in a bidirectional manner. T cells can be restimulated by fibroblasts through fibroblast MHC II (left) and T cells can activate fibroblasts through T-cell α_4 -integrin binding to fibroblast VCAM-1 (right). Figure was created with a licensed version of BioRender.com.

designation of macrophages is based on the surface markers C-C motif chemokine receptor 2 (CCR2) and CX3C motif chemokine receptor 1 (CX3CR1), which define their bone marrow or yolk sac origin and whether they are organ infiltrating as part of the immune response, or tissue-resident, respectively (11, 12). It is now clear that resident macrophages transmit signals and modify tissue properties, providing central homeostatic regulation of organ physiology. For example, monocyte-derived osteoclasts in the bone play a key role in remodeling in the context of mechanical stress (13); in skeletal muscle, resident macrophages orchestrate muscle regeneration in response to injury cooperating with multiple immune cells (14); in the brain, they participate in synaptic pruning and contribute to vascular and neural development by acting as endothelial cell chaperones (15); and in the heart, tissue-resident macrophages facilitate electrical conduction and synchronize cardiac rhythm (16).

Adaptive immune cells comprised of B and T lymphocytes (B and T cells) are uniquely characterized by having antigen specificity and immune memory. Upon antigen recognition by the B- and T cell receptors (BCR and TCR, respectively), they undergo clonal expansion and activation and release antibodies (plasma B cells), cytokines, and cytotoxic granules (T-helper CD4⁺ and T-cytotoxic CD8⁺ T cells, respectively), and differentiate into specialized subsets with distinctly unique and durable immune functions, which has been extensively reviewed (17, 18). In brief, cytotoxic CD8⁺ T cells recognize antigens presented by DC on major histocompatibility complex I (MHC-I), and helper CD4⁺ T cells do so through DC MHC-II, both of which can also be expressed by fibroblasts and participate in immune cell-fibroblast cross communication, as reviewed here. T and B cells mostly reside in the lymphoid organs and the gut and circulate throughout the body. However, recent evidence has revealed B- and T-cell pools that are transcriptionally different from the circulating pools residing in most organs, and possibly influenced by the organ stroma (19–21). A logistic regression model of human organs' single-cell sequencing data showed that while resident adaptive immune cells are transcriptionally similar in the human heart, kidney, and skeletal muscle, resident innate immune cells are highly tissue adaptive and less similar among different organs (4). Thus, immune cells and fibroblasts can influence each other, and innate immune cells are more shaped by specific organ niches than adaptive immune cells, yet all participate in immune and fibrotic responses through several mechanisms of action reviewed herein.

Profibrotic Functions of Immune Cells through Soluble Factor Secretion in Homeostasis and Disease

Innate and adaptive immune cells are sources of cytokines, some of which have profibrotic actions by signaling through their receptors expressed on fibroblasts. Under homeostatic conditions, macrophages communicate with fibroblasts through the release of platelet-derived growth factors (PDGFs) acting on platelet-derived growth factor receptor (PDGFR) expressed on fibroblasts (22). This communication results in the expression of prosurvival genes and has been demonstrated to act as a mechanism of homeostatic maintenance by resident macrophages at a steady state in multiple organs. In the heart, this axis is central to fibroblast

survival, as PDGFR α -deficient mice (*Pdgfra*^{-/-}) mice have 50% less fibroblasts in the heart than control littermates (23).

In the aftermath of heightened inflammation, profibrotic cytokines such as IL-13, IL-4, and IL-5 are released by organ-infiltrated T cell subsets (CD4⁺ T-helper type 2 cells-Th2), macrophages, and other innate immune cells (24). These cytokines are canonical drivers of type 2 immunity and serve to regulate tissue repair and fibrosis following injury in primarily mucosal tissues such as the intestines and the lung (25). IL-33 produced by epithelial cells and fibroblasts is often the initiator of such fibrotic responses in the lung, intestine, kidney, and heart (26). Preclinical acute kidney injury (AKI) studies reveal that IL-33 regulates fibrosis in the kidney and the heart through direct binding of IL-33 to cardiomyocytes, establishing IL-33 as a critical component of the kidney-heart axis in AKI-induced cardiomyopathy (27). IL-4, IL-5, and IL-13 have been implicated as key drivers of fibrosis in the skin, the adipose tissue, and the lung in preclinical models of inflammation and fibrosis (28–31). Besides these, cytokines not thought to be profibrotic in nature, such as IL-17 α and IFN γ , have also been recently described to have profibrotic actions on fibroblasts: IL-17 α , produced by CD4⁺ T-helper type 17 cells (Th17 cells) was shown to activate synovial fibroblasts, which then increased production of granulocyte macrophage colony-stimulating factor (GM-CSF), necessary for the development of rheumatoid arthritis in mice (32). In addition, interferon- γ (IFN γ) released by T-helper type 1 cells (Th1) is necessary for cardiac fibrosis in experimental models of heart failure and in cardiac repair, although protective against fibrosis in experimental autoimmune myocarditis and chronic viral myocarditis (33–36). Similarly, type I interferons have also recently been reported to act on fibroblasts in the onset of cardiac fibrosis in human hearts with congenital heart block (37, 38).

Perhaps the most widely recognized profibrotic cytokine is transforming growth factor β (TGF- β), which is synthesized and released by activated fibroblasts. TGF- β is also released, although to a lesser extent, by innate and adaptive immune cells. The reported production of TGF- β by CCR2⁺ macrophages and CD4⁺ T regulatory cells after phagocytosing apoptotic cells and antigen engagement, respectively, may also contribute to fibroblast activation and organ fibrosis (39). In the heart, infiltrating macrophage production of IL-12 α was deemed to be profibrotic, as IL-12 α -deficient mice had decreased fibrotic scarring in experimental models of myocardial infarction and in response to cardiac pressure overload (40). The absence of IL-12 α also resulted in a significant decrease in TAC-induced CD8⁺ T cell activation in the lung (41). Given that macrophages and fibroblasts are producers of IL-12 α , this finding may suggest that blocking their communication can lead to protection against cardiac and lung inflammation and fibrosis. Finally, the matrix protein osteopontin is highly expressed in atrial infiltrating monocytes in patients with persistent atrial fibrillation, and preclinical studies using combined hypertension, obesity, and mitral valve regurgitation (HOMER) mice identified macrophage-derived osteopontin as a critical driver of fibrosis and inflammatory fibroblast activation in atrial fibrillation (42).

Taken together, immune cell-fibroblast communication through a variety of soluble mediators that include cytokines, growth factors, and matrix metalloproteinases (MMPs), is

central to fibroblast function at the steady state and in response to tissue damage, and thus critical for survival (Fig. 1, A and B).

In addition, emerging literature demonstrates that immune cells establish direct interactions with fibroblasts and contribute to organ fibrosis. In the lung, in the onset of idiopathic pulmonary fibrosis (IPF), alveolar fibroblast activation is dependent on the proximity with alveolar macrophages. Mechanistic studies showed that only direct coculture of lung macrophages with lung fibroblasts resulted in profibrotic signals and fibroblast transformation, supporting that macrophages critically regulate pulmonary fibrosis in a spatially and contact-dependent manner (43). In addition, in preclinical pressure overload-induced HF, CD4⁺ T cells directly adhere to cardiac fibroblasts through α_4 -integrin-mediated adhesion and promote fibroblast TGF- β secretion and their transition to profibrotic myofibroblasts in an IFN γ -dependent manner (33) (Fig. 1, C and D), additionally supporting that physical interactions between immune cells and fibroblasts modulate tissue fibrosis.

FIBROBLAST CONTRIBUTION TO IMMUNE CELL RESPONSES DURING HOMEOSTASIS AND INFLAMMATION

“Immune-Like” Functions of Fibroblasts through Soluble Factor Secretion in Homeostasis and Disease

One of the best-characterized mechanisms for fibroblast-immune cell cross communication at steady state is the induction and production of colony-stimulating factor 1 (CSF1) with actions on its receptor CSF1R on macrophages, a highly conserved axis with similar function across multiple organs and microenvironments (44). Reticular fibroblast-derived CSF1 regulates splenic red pulp macrophage homeostasis, as shown in studies in which fibroblast deletion of CSF1 drastically diminished the density of red pulp macrophages. Fibroblast-specific deletion of CSF1 did not alter circulating CSF1 abundance, underscoring the importance of soluble factor-mediated fibroblast-macrophage cross talk in the tissue microenvironment (45). In response to inflammatory insults, fibroblasts also release several soluble factors that impact resident- and tissue-infiltrating immune cells and exacerbate the immune response. This is well exemplified in autoimmune diseases and is becoming evident as well in heart disease. Single-cell RNA sequencing (scRNA-Seq) from patients with rheumatoid arthritis (RA), an autoimmune disorder characterized by inflammation of the connective tissue that lines the joint capsule, identified a proinflammatory heparin-binding epidermal growth factor-like growth factor expressing set of macrophages, which was induced by prostaglandin E₂ (PGE₂) produced from synovial fibroblasts. These macrophages then in turn further activated synovial fibroblasts, and in an *in vitro* assay promoted their invasiveness (46). Samples from patients with RA have also revealed the expansion of a subset of fibroblasts located near the perivascular zone of the synovium characterized by increased proinflammatory and chemoattractive cytokines. Expansion of this subset in patients also correlated to increased leukocyte infiltration of the synovium (47), further supporting the

proinflammatory role of fibroblasts in the joint during autoimmunity.

In inflammatory bowel disease (IBD), an autoimmune disease characterized by gut inflammation in part due to an aberrant immune response, fibroblasts express higher levels of the receptor of the IL-6 family cytokine oncostatin M (OSMR) as compared with healthy controls, and these high-expressing OSMR fibroblasts sorted from patients with IBD showed enhanced expression of proinflammatory cytokines and chemoattractants such as IL-1 β , IL-6, CXCL9, and CXCL10 (48). Single cell data from patients with IBD also revealed a marked expansion of a subset termed inflammatory-associated fibroblasts compared with healthy controls, and the OSM/OSMR axis was identified as one of the most enriched pathways found in this population. In addition, a comparison between responders and nonresponders to anti-TNF α therapy, commonly used in IBD, revealed a strong correlation of nonresponders with the enhanced presence of inflammatory-associated fibroblasts (49). Fibroblasts expressing the proinflammatory and leukocyte-attracting molecules IL-6, IL-11, CXCL2, CXCL5, CCL2, and CCL7 have also been identified in patients with IBD in a separate study (50), altogether demonstrating that fibroblasts in the gut adopt immune-like functions that contribute to immune cell responses in IBD.

In the inflamed heart, cardiac fibroblasts sense myocardial damage and perpetuate the immune response through proinflammatory cytokine secretion and secretion of chemokines to recruit immune cells to sites of damage (Fig. 1C) (51). For example, mouse cardiac fibroblasts express CXCL9 and CXCL10, which serve as chemoattractants for Th1 in the onset of experimental heart failure induced by cardiac pressure overload (52). Liu et al. (53) used scRNA-Seq to demonstrate that dying cardiomyocytes induce TGF- β expression by fibroblasts. Fibroblasts are capable of self-activating via TGF- β induction and have also been shown to activate macrophages to be proinflammatory via TGF- β production as well (7, 53). Given that macrophages and fibroblasts are highly responsive to TGF- β and both can produce it during cardiac injury and stress, the failing heart represents a key site of proinflammatory cross talk for macrophages and fibroblasts. In all cases, fibroblasts adopt immune cell-like functions that contribute to organ homeostasis as well as inflammation.

Fibroblasts as Antigen-Presenting Cells to T Cells

DCs are professional antigen-presenting cells (APCs) that efficiently internalize and process antigens displayed by MHC-II molecules on the cell membrane. They also express the costimulatory molecules, CD80 and CD86 and induce CD4⁺ T cell responses upon antigen presentation. The fact that MHC-II can be induced on fibroblasts in several organs by proinflammatory cytokines such as IFN γ (54) has led to the appreciation of a novel immune-like role of fibroblasts as antigen-presenting cells at the sites of organ damage, and revealed a new possible target for future therapeutics for autoimmunity, heart disease, and cancer (Fig. 2).

In an experimental mouse model of RA, synovial fibroblasts were reported to function as APCs, taking up and processing citrullinated peptides contained by neutrophil extracellular traps (NETs) in the inflamed synovium through a receptor for advanced glycation end-product Toll-like receptor 9




Figure 2. Fibroblast-mediated antigen presentation plays essential functions in multiple disease contexts. **A:** rheumatoid arthritis. Synovial neutrophils release neutrophil extracellular traps (NETs) leading to the extrusion of nuclear material along with granules meant for defense against external pathogens. NETs also contain citrullinated peptides that are internalized by human synovial fibroblasts through the receptor for advanced glycation end-product Toll-like receptor (RAGE-TLR) endocytic pathway and IL-17B, which leads to the upregulation of MHC-II. Synovial fibroblasts can then present citrullinate peptides to antigen-specific CD4 T cells resulting in articular damage. **B:** inflammatory bowel disease. scRNA-Seq from patients with ulcerative colitis showed expansion of a stromal population only minimally present in healthy samples that resembles gene signatures from fibroblastic reticular stromal cells, which have been shown to express MHC-II. This population was marked by increased expression of CCL19 and CCL21 (T-cell recruitment), TNFSF14/LIGHT (T-cell costimulation), and MHC-II invariant chain (CD74). CD74 serves as a chaperone to MHC-II and helps prevent its disassembly in the absence of bound antigen. **C:** lung cancer. Fibroblasts from both human tumor samples and a murine model of lung cancer express MHC-II in an IFN γ -dependent manner. Fibroblast MHC-II expression leads to restricted tumor growth and increased survival by enhancing cytotoxicity and cytokine secretion of tumor-infiltrating T cells. In addition, fibroblast secreted C1q acts as a pro-survival signal for T cells within the tumor through an unknown mechanism. **D:** heart failure. In a model of pressure overload-induced HF, infiltrating T cells can bind to CFBs through α_4 -integrin leading to autocrine TGF- β production and transformation into myofibroblasts. CFBs constitutively express CD80 a coreceptor for T-cell activation, and Th1 cell-secreted IFN γ induces expression of MHC-II allowing for cardiac peptides internalized by CFBs to be presented to infiltrating T cells promoting the progression of adverse cardiac remodeling and inflammation. This is mirrored in human patients with dilated cardiomyopathy as those that received left ventricular assist devices designed to lessen the burden on the failing heart showed a decline in CFB human leukocyte antigen-DR isotype (HLA-DR) expression by scRNA-Seq. CFBs, cardiac fibroblasts; HF, heart failure; MHC-II, major histocompatibility complex II; TGF- β , transforming growth factor β . Figure was created with a licensed version of BioRender.com.

(RAGE-TLR9)-dependent process. This was regulated by IL-17 β and resulted in presentation of the processed peptides on MHC-II molecules and activation of infiltrating CD4⁺ T cells (55) (Fig. 2A). Similarly, in IBD, single cell data from patients showed expansion of a subset of fibroblasts expressing the invariant chain of MHC-II, CD74, critical for MHC-II processing and trafficking to the cell surface (56). CD74⁺ fibroblasts also showed upregulation of CCL19 and CCL21 and the T cell costimulatory TNF-superfamily ligand (TNFSF14/LIGHT), further suggesting that gut fibroblasts contribute to T cell immune responses in the gut potentially through antigen presentation (Fig. 2B). Perhaps one of the better characterized fibroblasts as APCs are tumor-

associated fibroblasts (57, 58). In human lung non-small cell carcinoma, as well as in a murine model of lung cancer, MHC-II is induced by IFN γ in fibroblasts. Fibroblast-specific deletion of MHC-II showed reduction in CD4 T cell expansion within the tumor, decreased survival, and increased tumor growth, whereas MHC-II-expressing tumor-associated fibroblasts promoted CD4 T cell survival through secretion of the complement protein C1q (57) (Fig. 2C).

Cardiac fibroblasts (CFBs) can also express MHC-II and function as APCs in the context of cardiac inflammation induced by transverse aortic constriction (TAC) and by *T. cruzi* infection in mice. Use of the Nur77^{GFP} mouse, a reporter for active antigen engagement of the T cell receptor,

demonstrated that cardiac infiltrated CD4⁺ T cells are restimulated by their cognate antigen by local APCs in the heart (59). CFBs also responded to IFN γ with upregulation of MHC-II and bare functional antigen uptake, processing, and presentation machinery, reiterating their role as APCs (Fig. 2D). *Tcf21^{Cre}-Mhcii^{fl/fl}* mice receiving TAC had significantly attenuated adverse cardiac pathology, including less perivascular fibrosis and preserved cardiac systolic function, compared with controls receiving TAC, demonstrating that antigen presentation by CFBs to CD4⁺ T cells is necessary for T cell-mediated adverse cardiac remodeling in the pressure-overloaded heart (60). The role of CFB antigen presentation in adverse cardiac remodeling in humans is also supported by scRNA-Seq data that show CFB HLA-DR expression in patients with dilated cardiomyopathy that is then reduced after implementation of a left ventricular assist device, which lessens the burden of HF (61).

Taken together, fibroblasts are immunologically active in several disease processes both through soluble factor secretion and direct fibroblast-T cell cross talk through antigen presentation.

CARDIAC FIBROSIS AND INFLAMMATION: REPARATIVE, REACTIVE, AND INVOLVEMENT IN HEART FAILURE

Cellular States of Cardiac Fibroblasts and the Influence of Cardiac Inflammation

HF is a widespread syndrome characterized by impaired cardiac function, which can arise in response to acute injuries originating in the myocardium, or in response to long-standing systemic stressors that force the heart to adapt to meet metabolic demand. CFBs are a dominant stromal cell in the heart, and are present in both the right and left ventricles, which each have distinct ECM properties and mechanisms of fibrotic remodeling under healthy development and under diseased conditions, as has been elegantly reviewed previously (62). Critically, CFBs have high phenotypic plasticity required to respond to the demands of the heart at steady state, as well as to repair and protect an organ with limited reparative capacity under pathophysiological circumstances. In cases of massive cardiomyocyte death, they adapt to participate in replacement fibrosis, wherein the accumulation of newly formed ECM takes the place of dying and apoptotic cardiomyocytes. This is a reparative process that allows for continued integrity of the myocardium without which the myocardium would become thin and finally rupture. In other cases of cardiac pathology, in which substantial myocardial cell death does not occur, accumulation of excessive ECM occurs in what is termed reactive fibrosis. Both types of fibrosis are modulated by the response of CFBs to various neurohormonal, mechanosensitive, and immune-mediated factors and contribute to stiffening of the heart, which often leads to arrhythmias and defective contractile and relaxation function. As a result, the presence and extent of cardiac fibrosis is associated with a worsening heart failure prognosis (63).

Single cell sequencing has demonstrated regional variation in the transcriptomic expression profiles of fibroblasts based on their relative locations, as well as within the heart, and

samples from patients with advanced-stage HF show expansion of activated CFBs that express well-known markers of activation and ECM reorganization (4, 64, 65). Interestingly, comparisons of CFB expression profiles between patients with hypertrophic, dilated, and ischemic cardiomyopathy show remarkably little differences. One explanation for these similarities despite different etiologies could be that these samples are taken from patients with late-stage HF and fibrotic pathways may converge to a common point in chronic HF. Thus, using preclinical studies to understand the composition of the fibroblast pool and specific mechanisms of immune-mediated fibroblast activation in different HF etiologies is of paramount importance.

In a model of myocardial infarction (MI) in mice, Farbehi et al. (5) showed distinct quiescent CFB populations at 3 and 7 days after injury that differed in expression of Sca-1. Activated CFBs then transitioned into myofibroblast subpopulations with profibrotic with upregulated *Tgfb1* and antifibrotic signatures including *Wisp2* and *Sfrp2*, which encode proteins with roles in inhibiting profibrotic WNT signaling (5). Within 4 wk after MI, matrifibrocytes, a subset of fibroblasts showing increased expression of chondrocyte-associated genes, are found in the infarcted area and may play important roles in scar maturation and maintenance (66). Analysis in an angiotensin II (ANG II)-induced hypertension mouse model of reactive fibrosis showed activated fibroblasts expressing *Thbs4* and *Cilp* as the most fibrogenic cell types while not expressing α smooth muscle actin (α SMA), a canonical marker of myofibroblast transformation (67). Similarly, in a model of pressure overload induced by TAC in mice, the transcriptional profiles of control and TAC mice at 14 and 28 days after surgery were used to identify different clusters of fibroblasts that expand in response to TAC. In addition, these experiments revealed that the gene *Thbs4*, encoding the glycoprotein thrombospondin-4, was reported as a key gene expressed in their highest-expressing ECM cardiac fibroblast subset as well as a subset of interferon responsive fibroblasts (68).

Cardiac fibrosis is also characterized by fibroblast proliferation in addition to ECM production and transformation to myofibroblasts. There is emerging evidence that fibroblasts can enter a proliferation-resistant state, also known as senescent-like state, with reduced ECM secretion, delineating this fibroblast subset from others that exert profibrotic action. These are characterized by the expression of senescence markers such as SA B-Gal, p53, and p16 in experimental models of myocardial infarction and cardiac pressure overload. Genetic ablation of p53 or p16 in mice subjected to cardiac pressure overload showed increased fibrosis, whereas AAV9 expression of CCN1, an inducer of cellular senescence, led to a 50% reduction in perivascular fibrosis (69), supporting that the cardiac fibroblast senescent like state can prevent excessive fibrosis. However, while this may be beneficial in the short term, the presence of senescent fibroblasts may be detrimental in the long term, a concept deserving further investigation.

The transition of fibroblasts into different states is regulated temporally through a variety of regulators, including expression of posttranscriptional regulators such as the RNA-binding protein muscleline-like 1 (MBNL1), which induces and stabilizes myofibroblast phenotypes (70). Interestingly, although myofibroblasts are canonically characterized by the

expression of α smooth muscle actin (encoded by *Acta2*), CFB-specific deletion of *Acta2* did not affect cardiac fibrosis, ejection fraction, or mouse survival post-MI, underscoring how functionally redundant mechanisms are in place in this population of cells (71). However, despite these redundancies, the heterogeneity of the CFB pool, and the plasticity of CFB phenotypes, the effects of specific CFB subsets on reparative versus reactive fibrosis are concrete. For instance, while CFBs are the cardiac cell type in the failing heart expressing the highest levels of family with sequence similarity 114 member A1 (*FAM114A1*), a gene regulating cardiac fibroblast ECM protein expression and TGF- β -dependent migration, CFB-specific deletion of *FAM114A1* ameliorates adverse fibrotic remodeling and impaired contractility post-MI, without inducing cardiac rupture, highlighting the different mechanisms that regulate CFB activity in reparative and reactive fibrosis (72).

Fibrosis in Heart Failure with Reduced Ejection Fraction: Shaping and Shifting the Fibroblast Pool

Heart failure with reduced ejection fraction (HFrEF) is a category of HF etiologies in which cardiac contractility is impaired. HFrEF can be further subdivided into ischemic and nonischemic HF, reflecting the nature of the insult/injury experienced by the myocardium. In the former, spatial and temporal alterations in fibroblast activity and inflammation propagate reparative fibrosis as they work to scavenge necrotic tissue and deposit a collagenous scar in its place to prevent cardiac rupture. In chronic ischemic HF and nonischemic HFrEF, when the ventricle experiences hemodynamic stress and stimuli unrelated to CM death, reactive fibrosis occurs. Substantial effort has been made to understand the molecular and cellular mechanisms underlying these different modes of fibrosis, and their subsequent effects on impaired cardiac contractility.

As discussed in this review, fibroblasts and immune cells interface regularly in the heart, as well as in other organs, to perpetuate fibrotic remodeling. In experimental pressure overload, we have recently demonstrated that tuning CD4⁺ T cell activation directly modulates cardiac fibrotic remodeling through direct T cell:CFB interactions (73). Furthermore, in addition to their interactions with each other in the myocardium, how these cell types interact with the ECM are of particular importance, as the ECM contains proteins that modulate fibrotic remodeling. For instance, asporin, an inhibitor of TGF- β 1, has protective roles in HFrEF, both through inhibiting reactive fibrosis in TAC and preserving cardiomyocyte viability in ischemia reperfusion injury (74). Through recent efforts, key molecular mechanisms underlying interactions between CFBs and the myocardium have emerged. For example, the yes-associated protein (YAP)/transcriptional coactivator with PDZ-binding motif (TAZ) complex, a transcription factor complex serving as effectors of the Hippo signaling pathway, is a recognized mechanotransduction pathway by which fibroblasts recognize and respond to alterations in the ECM (75). Nuclear localization of YAP occurs in cells following cytoskeletal sensing of mechanical strain, and are inhibited by phosphorylation by Hippo pathway kinases, large tumor suppressor kinase (LATS). Deletion of *Lats* in mice resulted in unbalanced cardiac fibroblast transformation and pervasive myocardial fibrosis, reduced EF, and increased CFB-derived expression of *Ccl7*

(76). In primary human cardiac stromal cells, pharmacological targeting of YAP by verteporfin downregulated pathways related to ECM organization, cell migration, inflammation, and cytokine production as measured by RNA sequencing (77). Deletion of YAP/TAZ in cardiac fibroblasts using the *Col1a2*^{Cre} system in mice undergoing MI resulted in reduced cardiac fibroblast cytokine secretion, resulting in reductions in F4/80⁺ macrophage migration to the infarct and border zone, alongside reduced fibrotic remodeling (78). More recently, YAP deletion in myeloid cells, and targeting myeloid YAP with nanoparticles resulted in decreased fibrosis induced by TAC through mechanisms that involve an antifibrotic and proresolution phenotype of macrophages deficient in YAP (79). Thus, the cell specificity of the YAP pathway is important in the interphase of the fibrotic and immune responses during reactive fibrosis in mice.

In ischemic HF, the activity by fibroblasts and immune cells is temporally regulated, reflecting the transition from the scavenging of ischemic necrotic tissue to the development of reparative fibrosis. Perpetuating this transition are phases of inflammation, in which infiltrating and resident immune cells play distinct roles in acute and chronic time points post-MI. How these cells affect the remodeling myocardium is highly stage specific. For instance, CD4⁺ T cells exhibit biphasic cardiac infiltration, and the later infiltrating cells specifically correlate to the progression of chronic HF (80). Similarly, the cardiac fibroblast pool is highly heterogeneous, with specific subpopulations playing key roles in different phases post-MI. Single cell analysis of isolated fibroblasts from murine hearts after MI revealed a population of infarct-associated periostin (*postn*⁺) fibroblasts emerging post-MI that play active roles in reparative fibrosis (81). This is not unlike the temporal phases of fibrotic remodeling in skin, another instance of reparative fibrotic remodeling, wherein early and late time points are correlated with proinflammatory then profibrotic polarizations of fibroblasts in early then late time points, respectively, of wound healing (82). Following the reparative phase of MI, resolution of inflammation and fibrosis is achieved in part through the recruitment of anti-inflammatory cells, such as T regulatory cells, which suppress proinflammatory cell activity and may directly attenuate fibroblast activity through reducing fibroblast α -SMA expression and secretion of matrix metalloproteinase 3 (83).

Interestingly, although the heart experiences very different stressors in nonischemic HF compared with ischemic HF, there are similarities in how fibroblasts propagate reactive fibrosis in this setting. For instance, TAC also expands a particular subgroup of highly proliferative fibroblasts, which are in this case endocardial-derived, demonstrating a degree of specialization similar to how MI shapes the fibroblast pool (84). In response to TAC, fibroblasts also experience temporally regulated changes in expression of genes associated with different states, stages of activation, and polarity, and ablation of early response proteins such as receptor tyrosine kinase-like orphan receptor 1 and 2 (*Ror1/2*) resulted in a hyperinflammatory cardiac state (85). Thus, the stages of fibroblast polarization and the times at which they occur have critical functions for inflammation and adverse cardiac remodeling in response to pressure overload. In addition, as with MI, CFBs are highly influenced by the state of the ECM at the acute and chronic

stages of pressure overload. Cardiac accumulation of chondroitin sulfate glycosaminoglycans (CS-GAGs), proteoglycans secreted by CFBs, has been linked to heightened inflammation and progression of HF. However, abrogated production of CS-GAGs through genetic deletion of chondroitin sulfate *N*-acetylgalactosaminyltransferase-2 in mice results in worsened cardiac dysfunction 2 wk after TAC, demonstrating that these factors have protective effects in the acute phase post-TAC, which may differ from their effects in chronic HF (86). This demonstrates that there are similarities in how the CFB pool is shaped in response to ischemic and nonischemic stimuli, and these similarities may be leveraged to devise therapeutic approaches that may be effective for both categories of etiologies. As an example, salinomycin, a polyether ionophore, was shown to attenuate pathological fibrotic remodeling in preclinical hypertension induced by angiotensin II and MI, likely by targeting several different pathways in CFBs and cardiomyocytes (87).

In conclusion, the alterations in the myocardium that drive impaired contractility in HFrEF are actively sensed by fibroblasts, and translate into global changes in CFB populations, polarization, and activity at distinct time points of acute and chronic HF. These are tightly regulated by the composition and type of immune response, as fibroblasts and immune cell types communicate in the heart and participate in myocardial repair and maladaptive remodeling (Fig. 3, top). Although the initiation and progression of ischemic versus nonischemic cardiac remodeling have distinct differences and involve distinct immune responses, there are also similarities in how CFBs respond to these stimuli and cross talk with immune cells, which may be leveraged in future therapeutic approaches.

Fibrosis in HFpEF: Hidden and Dispersed

Heart failure with preserved ejection fraction (HFpEF) is a complex multiorgan syndrome accounting for roughly 50% of HF diagnoses (88). Therapies that have been successful in treating HF in patients with reduced ejection fraction (HFrEF) often fail to do the same for patients with HFpEF. For example, the combination of sacubitril/valsartan (angiotensin receptor-neprilysin inhibitor), which was found to lower the rate of hospitalization for HF or death in patients with HFpEF, did not affect hospitalization rate or mortality in patients with HFpEF (89), despite rodent studies demonstrating that the drug treatment ameliorates cardiac fibrosis and cardiac expression of profibrotic genes in preclinical HFpEF (90). As HFpEF often presents in patients with many long-standing comorbidities (such as obesity, hypertension, age, and kidney disease), the HFpEF patient population is highly heterogeneous, complicating clinical diagnosis and treatment, as well as accurate/representative preclinical modeling (91). To identify specific mechanisms of HFpEF, including the progression of cardiac fibrosis and mechanisms of immune-mediated cardiac pathology, several rodent models inducing one or several HFpEF comorbidities are used, and as such, reveal potentially targetable axes in specific HFpEF patient subgroups.

Preclinical studies and improved noninvasive imaging techniques identify cardiac fibrosis in HFpEF, and associate cardiac fibrosis with poor patient outcomes. In patients, cardiovascular magnetic resonance (CMR) is frequently used to

measure fibrotic remodeling in patients—myocardial scars and focal fibrosis (often seen in ischemic and nonischemic HF) are measured by late gadolinium enhancement, while “diffuse” fibrosis, which includes microscopic interstitial fibrosis, is measured by T1 mapping (92). The latter quantifies the myocardial extracellular volume (ECV), which is a surrogate marker of dispersed interstitial fibrosis, and serves as an important predictor of adverse outcomes in HFpEF, demonstrating diffuse fibrosis that plays critical roles for HFpEF pathology despite its relatively subtle presentation (93). Endomyocardial biopsy samples from patients with HFpEF reveal increases in myocardial collagen I and III gene expression compared with non-HF controls, alongside increases in CD3⁺ CD11⁺ and CD45⁺ leukocytes as measured by immunohistological staining (94). Another study investigating endomyocardial biopsy samples found the prevalence of cardiac amyloidosis to be 14% of their HFpEF patient cohort, when oftentimes cardiac amyloidosis was not suspected (95). These patients experience abnormal amyloid deposition into the myocardium resulting in increased ventricular stiffness, and a study using histological assessment of cardiac fibrosis and amyloid deposition in HFpEF autopsy tissue indicated that the presence of this deposition is associated with greater cardiac fibrosis (96). Studies investigating the relationship between amyloid deposition, inflammation, and cardiac fibrosis are necessary to identify mechanisms by which these pathologies may synergize to impair cardiac relaxation. Despite clear evidence of myocardial ECM remodeling in HFpEF, the extent to which this impairs cardiac relaxation is disputed. The PIROUETTE phase 2 clinical trial testing pirfenidone, an antifibrotic agent approved for patients with idiopathic pulmonary fibrosis, successfully reduced myocardial ECV in patients with HFpEF (the primary outcome of the study), though left ventricular diastolic function was not impacted, suggesting that other factors other than bulk ECM volume contribute to diastolic dysfunction (97), such as cellular changes at the cardiomyocyte level. In addition, HFpEF endomyocardial biopsies have unique tissue signatures compared with HFrEF right ventricular septal tissue samples, in part characterized by a downregulation in fibrosis-related genes in HFpEF compared with HFrEF as measured by RNA sequencing (98). Thus, the processes governing fibrotic remodeling in HFpEF are likely categorically distinct from those in HFrEF, and may be regarded as simultaneously more subtle and more widespread than the focal fibrotic areas found in HFrEF.

Nevertheless, preclinical models have revealed novel mechanisms of fibrosis, and the intersections between fibroblast activity in the myocardium and the immune response in the context of HFpEF is as its infancy. Following clinical data demonstrating patients with HFpEF have increased circulating neutrophil abundance, neutrophil extracellular traps (NETs) were found to contribute to cardiac fibrosis and diastolic dysfunction using a salty drinking water—unilateral nephrectomy—aldosterone (SAUNA) murine HFpEF model. Inhibition of high mobility group box 1 protein (HMGB1), a potent damage-associated molecular pattern, reduced NET formation in the heart and ameliorated both diastolic dysfunction and fibrosis, possibly through impairing the recruitment of macrophages (99). Another major hallmark of HFpEF is metabolic syndrome, a highly proinflammatory condition,




Figure 3. Distinct presentations of cardiac fibrosis in clinical and preclinical heart failure (HF) with reduced vs. preserved ejection fraction (EF). *Top:* patients with ischemic or nonischemic HF with reduced EF (HFrEF) experience direct injury to the myocardium, resulting in a shifting of the heterogeneous fibroblast pool toward a refined population in response to changes in the extracellular matrix and inflammatory mediators. This results in focal depositions of collagen, which can be contrasted against the healthy myocardium. *Bottom:* in contrast, in patients with HF with preserved EF (HFpEF), cardiac remodeling occurs in response to perturbations originating from the systemic periphery, in which combined comorbidities, such as obesity, hypertension, and age, alter circulating metabolites, immune cells, inflammatory mediators, and lipid-derived products. This results in an overall reinforcement of the ventricular ECM by additional fibrotic proteins, increasing the overall compliance of the myocardium. Thus, fibrotic remodeling in HFpEF is more global, and less local, than in HFrEF. Figure was created with a licensed version of BioRender.com.

which particularly shapes the presentation of cardiometabolic HFpEF. In mice, the combination of advanced age, high-fat diet, and intraperitoneal injection of deoxycorticosterone pivalate induces preclinical HFpEF and assembly of the NOD-like receptor protein 3 (NLRP3) inflammasome on hyperacetylated cardiac mitochondria, driving increases in cardiac IL-1 β and IL-18 abundance. Elevating cardiac concentrations of β -hydroxybutyrate (β -OHB), a dominant ketone body that is decreased in circulation in patients with HFpEF, decreased mitochondrial hyperacetylation and ameliorated cardiac fibrosis and improved cardiac function (100). Finally, preclinical HFpEF models induced by the combination of three hits—high-fat diet to induce obesity, N^G -nitro-L-arginine methyl ester (L-NAME) to induce hypertension, and cardiomyocyte-specific deletion of the L-type Ca^{2+} channel β_{2a} -subunit—resulted in increased cardiac CD206 $^{+}$ CD68 $^{+}$ macrophages alongside increased gene expression of *Tgfb*, followed by the onset of robust perivascular and interstitial fibrosis (101). This suggests cross talk between cardiac fibroblasts, immune cells, and cardiomyocytes in the context of metabolic and mechanical stressors induced by combined comorbidities drive HFpEF phenotypes.

Although these studies are critical for elucidating how drivers of HFpEF elicit fibrotic responses, these data are largely correlative, and lack mechanistic interrogations of direct interactions between inducers of HFpEF, immune cells, and fibroblasts, as have been identified in HFrEF etiologies. In addition, studies identifying mechanisms of immune-mediated fibrosis in specific subsets of the population with patients with HFpEF (e.g., cardiometabolic HFpEF or cardiorenal HFpEF) will be necessary to understand how systemic stress from HFpEF comorbidities translates to alterations in myocardial ECM composition.

Epigenetic modifications, such as the inhibition of histone deacetylases (HDACs), have been shown to improve myocardial relaxation without altering blood pressure in a murine model using uniphrectomy with deoxycorticosterone acetate-salt to induce preclinical HFpEF. In this model, although there is no detectable fibrosis by picrosirius red staining in HFpEF mice, treatment with a clinical stage HDAC inhibitor Givinostat recovered alterations in the ECM that contributed to increased myocardial stiffness in vivo and blocked cardiac fibroblast activation in vitro (102). In addition, mechanistic studies interrogating the potential

sources of myofibroblasts in tissue have identified endothelial to mesenchymal transition (endo-MT), the process by which endothelial cells transition into a mesenchymal phenotype, as a possible mechanism of fibrosis in HFpEF. Murine studies using the SAUNA HFpEF model, which models cardiorenal HFpEF, identified endo-MT in the kidneys of HFpEF mice by the upregulation of endo-MT mRNA transcripts, namely, platelet-derived growth factor receptor β (*pdgfr β*), *snail*, fibronectin (*fn*), vimentin (*vim*), and fibroblast-specific protein 1 (*fsp1*), as well as by histology identifying CD31⁺ cells expressing smooth muscle actin. Interestingly, the heart did not show upregulation of these transcripts, leading the authors to conclude they did not observe cardiac endo-MT at the time of analysis (103). Whether endo-MT occurs earlier or later in HFpEF or whether it occurs in specific HFpEF subsets as a consequence of particular systemic and cardiac stressors remain ongoing areas of interest. Finally, low level transcutaneous vagus nerve stimulation (LLTS) blunted cardiac fibrosis, diastolic dysfunction, and cardiac macrophage infiltration Dahl salt-sensitive rats fed high-salt diet (104), revealing a novel intersection between the nervous, immune, and cardiovascular systems in mediating fibrotic remodeling in HFpEF.

Taken together, while cardiac fibrosis is a pathological hallmark of both HFpEF and HFrEF, fibrosis in HFpEF is somewhat phenotypically distinct from that in HFrEF. Unlike in HFrEF, where injuries occur in the myocardium that directly invoke local and recruited profibrotic responses, combined comorbidities induce systemic alterations in circulating metabolic and inflammatory mediators, which ultimately inflame the heart in HFpEF. Thus, rather than remodeling with focal depositions of collagen that contrast from healthy myocardium, there is a global deposition of ECM proteins that increases the stiffness of the chamber as a whole and impacts diastolic function (Fig. 3, bottom). Through preclinical studies, perhaps specific mechanisms of immune-mediated fibrosis can assist in revealing therapeutic targets in patients, or subsetting patients with HFpEF by the presentation or progression of fibrosis to assist in diagnosis.

CONCLUDING REMARKS

The coexistence and communication of fibroblasts and immune cells in organs through soluble factors and cellular contact reveals how these two distinct cell types participate in coordinated responses central to maintaining tissue homeostasis and rapidly promoting tissue repair after injury. Anti-inflammatory therapies are effective at treating autoimmune diseases such as RA and IBD, whereas antifibrotic therapies have only showed success in very specific organ conditions. In HF, no anti-inflammatory or antifibrotic therapies have been fully successful to date. The emerging knowledge of fibroblasts and immune cell heterogeneity and plasticity imprinted at the organ niche, where both cell types communicate and adopt functions from each other, offers the opportunity to identify potential novel therapeutic targets in organ inflammation and fibrosis. In addition, while fibrotic diseases such as HF are known to have sex-specific clinical phenotypes (105), the molecular mechanisms underlying these differences are poorly understood. Although this sexual dimorphism may be attributed to ECM compositional

differences or sex-dependent inflammatory mechanisms (106, 107), we propose that studying whether the intersection between fibroblast activity and inflammation is sex dependent will reveal greater mechanistic insight into the pathophysiology of HF, compared with studying these entities in isolation of one another. Despite similarities across organs, fibroblast states are also unique depending on their location in the body and in the immune response triggered when a fibrotic response needs to be put into place. Understanding these fibroblast-immune cell nodes of communication during homeostasis and how these are modified in disease will be central to finding successful therapeutics for diseases such as heart failure, where the inflammatory and fibrotic responses coexist.

GRANTS

This work was supported by National Heart, Lung, and Blood Institute Grants R01-HL144477 and R01-HL165725 (to P.A.) and F31-HL159907 (to S.S.); American Heart Association Predoctoral Grants 906561 (to S.S.) and 1019412 (to B.T.); and Beacon Student Success Fellowship (to N.H.).

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the authors.

AUTHOR CONTRIBUTIONS

S.S., B.T., N.W. and P.A. prepared figures; S.S., B.T., N.W. and P.A. drafted manuscript; S.S., B.T. and P.A. edited and revised manuscript; S.S., B.T., N.W. and P.A. approved final version of manuscript.

REFERENCES

1. Tallquist MD. Cardiac fibroblast diversity. *Annu Rev Physiol* 82: 63–78, 2020. doi:10.1146/annurev-physiol-021119-034527.
2. Humeres C, Frangogiannis NG. Fibroblasts in the infarcted, remodeling, and failing heart. *JACC Basic Transl Sci* 4: 449–467, 2019. doi:10.1016/j.jacbs.2019.02.006.
3. Frangogiannis NG. Cardiac fibrosis. *Cardiovasc Res* 117: 1450–1488, 2021. doi:10.1093/cvr/cvaa324.
4. Litvinčuková M, Talavera-López C, Maatz H, Reichart D, Worth CL, Lindberg EL, Kanda M, Polanski K, Heinig M, Lee M, Nadelmann ER, Roberts K, Tuck L, Fasouli ES, DeLaughter DM, McDonough B, Wakimoto H, Gorham JM, Samari S, Mahbubani KT, Saeb-Parsy K, Patone G, Boyle JJ, Zhang H, Zhang H, Viveiros A, Oudit GY, Bayraktar OA, Seidman JG, Seidman CE, Nosedá M, Hubner N, Teichmann SA. Cells of the adult human heart. *Nature* 588: 466–472, 2020. doi:10.1038/s41586-020-2797-4.
5. Farbehi N, Patrick R, Dorison A, Xaymardan M, Janbandhu V, Wystub-Lis K, Ho JWK, Nordon RE, Harvey RP. Single-cell expression profiling reveals dynamic flux of cardiac stromal, vascular and immune cells in health and injury. *eLife* 8: e43882, 2019. doi:10.7554/eLife.43882.
6. Hanna A, Frangogiannis NG. Inflammatory cytokines and chemokines as therapeutic targets in heart failure. *Cardiovasc Drugs Ther* 34: 849–863, 2020. doi:10.1007/s10557-020-07071-0.
7. Frangogiannis NG. Transforming growth factor- β in myocardial disease. *Nat Rev Cardiol* 19: 435–455, 2022. doi:10.1038/s41569-021-00646-w.
8. Muhl L, Genové G, Leptidis S, Liu J, He L, Mocci G, Sun Y, Gustafsson S, Buyandelger B, Chivukula IV, Segerstolpe Å, Raschperger E, Hansson EM, Björkegren JLM, Peng XR, Vanlandewijck M, Lendahl U, Betsholtz C. Single-cell analysis uncovers fibroblast heterogeneity and criteria for fibroblast and mural cell identification and discrimination.

- Nat Commun* 11: 3953, 2020 [Erratum in *Nat Commun* 11: 4493, 2020]. doi:10.1038/s41467-020-17740-1.
9. Van Kaer L, Postoak JL, Song W, Wu L. Innate and innate-like effector lymphocytes in health and disease. *J Immunol* 209: 199–207, 2022. doi:10.4049/jimmunol.2200074.
10. Natoli G, Ostuni R. Adaptation and memory in immune responses. *Nat Immunol* 20: 783–792, 2019. doi:10.1038/s41590-019-0399-9.
11. Yap J, Irei J, Lozano-Gerona J, Vanaprucks S, Bishop T, Boisvert WA. Macrophages in cardiac remodelling after myocardial infarction. *Nat Rev Cardiol* 20: 373–385, 2023. doi:10.1038/s41569-022-00823-5.
12. Epelman S, Lavine KJ, Randolph GJ. Origin and functions of tissue macrophages. *Immunity* 41: 21–35, 2014. doi:10.1016/j.immuni.2014.06.013.
13. Takayanagi H. Interaction between the immune system and bone metabolism: an emerging field of osteoimmunology. *Proc Jpn Acad Ser B Phys Biol Sci* 83: 136–143, 2007. doi:10.2183/pjab.83.136.
14. Tidball JG. Regulation of muscle growth and regeneration by the immune system. *Nat Rev Immunol* 17: 165–178, 2017. doi:10.1038/nri.2016.150.
15. Paolicelli RC, Gross CT. Microglia in development: linking brain wiring to brain environment. *Neuron Glia Biol* 7: 77–83, 2011. doi:10.1017/S1740925X12000105.
16. Hulsmans M, Clauss S, Xiao L, Aguirre AD, King KR, Hanley A, Hucker WJ, Wülfers EM, Seemann G, Courties G, Iwamoto Y, Sun Y, Savol AJ, Sager HB, Lavine KJ, Fishbein GA, Capen DE, Da Silva N, Miquero L, Wakimoto H, Seidman CE, Seidman JG, Sadreyev RI, Naxerova K, Mitchell RN, Brown D, Libby P, Weissleder R, Swirski FK, Kohl P, Vinegoni C, Milan DJ, Ellinor PT, Nahrendorf M. Macrophages facilitate electrical conduction in the heart. *Cell* 169: 510–522.e20, 2017. doi:10.1016/j.cell.2017.03.050.
17. Sanz I, Wei C, Jenks SA, Cashman KS, Tipton C, Woodruff MC, Hom J, Lee FE. Challenges and opportunities for consistent classification of human B cell and plasma cell populations. *Front Immunol* 10: 2458, 2019. doi:10.3389/fimmu.2019.02458.
18. Saigusa R, Winkels H, Ley K. T cell subsets and functions in atherosclerosis. *Nat Rev Cardiol* 17: 387–401, 2020. doi:10.1038/s41569-020-0352-5.
19. Adamo L, Rocha-Resende C, Lin CY, Evans S, Williams J, Dun H, Li W, Mpoy C, Andrey PS, Rogers BE, Lavine K, Kreisel D, Artyomov M, Randolph GJ, Mann DL. Myocardial B cells are a subset of circulating lymphocytes with delayed transit through the heart. *JCI Insight* 5: e134700, 2020. doi:10.1172/jci.insight.134700.
20. Martini E, Kunderfranco P, Peano C, Carullo P, Cremonesi M, Schorn T, Carriero R, Termanini A, Colombo FS, Jachetti E, Panico C, Faggian G, Fumero A, Torracca L, Molgora M, Cibella J, Pagiatakis C, Brummelman J, Alvisi G, Mazza EMC, Colombo MP, Lugli E, Condorelli G, Kallikourdis M. Single-cell sequencing of mouse heart immune infiltrate in pressure overload-driven heart failure reveals extent of immune activation. *Circulation* 140: 2089–2107, 2019. doi:10.1161/CIRCULATIONAHA.119.041694.
21. Masopust D, Soerens AG. Tissue-resident T cells and other resident leukocytes. *Annu Rev Immunol* 37: 521–546, 2019. doi:10.1146/annurev-immunol-042617-053214.
22. Wynn TA, Barron L. Macrophages: master regulators of inflammation and fibrosis. *Semin Liver Dis* 30: 245–257, 2010. doi:10.1055/s-0030-1255354.
23. Ivey MJ, Kuwabara JT, Riggsbee KL, Tallquist MD. Platelet-derived growth factor receptor- α is essential for cardiac fibroblast survival. *Am J Physiol Heart Circ Physiol* 317: H330–H344, 2019. doi:10.1152/ajpheart.00054.2019.
24. Zhu J. T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production. *Cytokine* 75: 14–24, 2015. doi:10.1016/j.cyt.2015.05.010.
25. Gieseck RL 3rd, Wilson MS, Wynn TA. Type 2 immunity in tissue repair and fibrosis. *Nat Rev Immunol* 18: 62–76, 2018. doi:10.1038/nri.2017.90.
26. Kotsiou OS, Gourgoulis KI, Zarogiannis SG. IL-33/ST2 axis in organ fibrosis. *Front Immunol* 9: 2432, 2018. doi:10.3389/fimmu.2018.02432.
27. Florens N, Kasam RK, Rudman-Melnick V, Lin SC, Prasad V, Molkenin JD. Interleukin-33 mediates cardiomyopathy after acute kidney injury by signaling to cardiomyocytes. *Circulation* 147: 746–758, 2023. doi:10.1161/CIRCULATIONAHA.122.063014.
28. Nguyen JK, Austin E, Huang A, Mamalis A, Jagdeo J. The IL-4/IL-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targets. *Arch Dermatol Res* 312: 81–92, 2020. doi:10.1007/s00403-019-01972-3.
29. Arndt L, Lindhorst A, Neugebauer J, Hoffmann A, Hobusch C, Alexaki VI, Ghosh A, Blüher M, Wolfrum C, Glaß M, Gericke M. The role of IL-13 and IL-4 in adipose tissue fibrosis. *Int J Mol Sci* 24: 5672, 2023. doi:10.3390/ijms24065672.
30. D'Arcy Q, Gharaee-Kermani M, Zhilin-Roth A, Macoska JA. The IL-4/IL-13 signaling axis promotes prostatic fibrosis. *PLoS One* 17: e0275064, 2022. doi:10.1371/journal.pone.0275064.
31. Zhang J, Qiu J, Zhou W, Cao J, Hu X, Mi W, Su B, He B, Qiu J, Shen L. Neuropilin-1 mediates lung tissue-specific control of ILC2 function in type 2 immunity. *Nat Immunol* 23: 237–250, 2022. doi:10.1038/s41590-021-01097-8.
32. Hirota K, Hashimoto M, Ito Y, Matsuura M, Ito H, Tanaka M, Watanabe H, Kondoh G, Tanaka A, Yasuda K, Kopf M, Potocnik AJ, Stockinger B, Sakaguchi N, Sakaguchi S. Autoimmune Th17 cells induced synovial stromal and innate lymphoid cell secretion of the cytokine GM-CSF to initiate and augment autoimmune arthritis. *Immunity* 48: 1220–1232.e5, 2018. doi:10.1016/j.immuni.2018.04.009.
33. Nevers T, Salvador AM, Velazquez F, Ngwenyama N, Carrillo-Salinas FJ, Aronovitz M, Blanton RM, Alcaide P. Th1 effector T cells selectively orchestrate cardiac fibrosis in nonischemic heart failure. *J Exp Med* 214: 3311–3329, 2017. doi:10.1084/jem.20161791.
34. Fairweather D, Frisancho-Kiss S, Yusung SA, Barrett MA, Davis SE, Gatewood SJL, Njoku DB, Rose NR. Interferon- γ protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines transforming growth factor- β 1, interleukin-1 β , and interleukin-4 in the heart. *Am J Pathol* 165: 1883–1894, 2004. doi:10.1016/s0002-9440(10)63241-5.
35. Hofmann U, Beyersdorf N, Weirather J, Podolskaya A, Bauersachs J, Ertl G, Kerkau T, Frantz S. Activation of CD4+ T lymphocytes improves wound healing and survival after experimental myocardial infarction in mice. *Circulation* 125: 1652–1663, 2012. doi:10.1161/CIRCULATIONAHA.111.044164.
36. Afanasyeva M, Georgakopoulos D, Fairweather D, Caturegli P, Kass DA, Rose NR. Novel model of constrictive pericarditis associated with autoimmune heart disease in interferon- γ -knockout mice. *Circulation* 110: 2910–2917, 2004. doi:10.1161/01.CIR.0000147538.92263.3A.
37. Cui Y, Zheng Y, Liu X, Yan L, Fan X, Yong J, Hu Y, Dong J, Li Q, Wu X, Gao S, Li J, Wen L, Qiao J, Tang F. Single-cell transcriptome analysis maps the developmental track of the human heart. *Cell Rep* 26: 1934–1950.e1935, 2019. doi:10.1016/j.celrep.2019.01.079.
38. Suryawanshi H, Clancy R, Morozov P, Halushka MK, Buyon JP, Tuschl T. Cell atlas of the foetal human heart and implications for autoimmune-mediated congenital heart block. *Cardiovasc Res* 116: 1446–1457, 2020. doi:10.1093/cvr/cvz257.
39. Hulsmans M, Sam F, Nahrendorf M. Monocyte and macrophage contributions to cardiac remodeling. *J Mol Cell Cardiol* 93: 149–155, 2016. doi:10.1016/j.jmcc.2015.11.015.
40. Kan X, Wu Y, Ma Y, Zhang C, Li P, Wu L, Zhang S, Li Y, Du J. Deficiency of IL-12p35 improves cardiac repair after myocardial infarction by promoting angiogenesis. *Cardiovasc Res* 109: 249–259, 2016. doi:10.1093/cvr/cvz255.
41. Bhattarai U, He X, Xu R, Liu X, Pan L, Sun Y, Chen JX, Chen Y. IL-12 α deficiency attenuates pressure overload-induced cardiac inflammation, hypertrophy, dysfunction, and heart failure progression. *Front Immunol* 14: 1105664, 2023. doi:10.3389/fimmu.2023.1105664.
42. Hulsmans M, Schloss MJ, Lee I-H, Bapat A, Iwamoto Y, Vinegoni C et al. Recruited macrophages elicit atrial fibrillation. *Science* 381: 231–239, 2023. doi:10.1126/science.abq3061.
43. Novak CM, Sethuraman S, Luikart KL, Reader BF, Wheat JS, Whitson B, Ghadiali SN, Ballinger MN. Alveolar macrophages drive lung fibroblast function in cocultures of IPF and normal patient samples. *Am J Physiol Lung Cell Mol Physiol* 324: L507–L520, 2023. doi:10.1152/ajplung.00263.2022.
44. Buechler MB, Fu W, Turley SJ. Fibroblast-macrophage reciprocal interactions in health, fibrosis, and cancer. *Immunity* 54: 903–915, 2021. doi:10.1016/j.immuni.2021.04.021.
45. Bellomo A, Mondor I, Spinelli L, Lagueyrie M, Stewart BJ, Brouilly N, Malissen B, Clatworthy MR, Bajenoff M. Reticular fibroblasts expressing the transcription factor WT1 define a stromal niche that

- maintains and replenishes splenic red pulp macrophages. *Immunity* 53: 127–142.e127, 2020. doi:10.1016/j.immuni.2020.06.008.
46. Kuo D, Ding J, Cohn IS, Zhang F, Wei K, Rao DA, Roza C, Sokhi UK, Shanaj S, Oliver DJ, Echeverria AP, DiCarlo EF, Brenner MB, Bykerk VP, Goodman SM, Raychaudhuri S, Ratsch G, Ivashkiv LB, Donlin LT. HBEGF⁺ macrophages in rheumatoid arthritis induce fibroblast invasiveness. *Sci Transl Med* 11: eaau8587, 2019. doi:10.1126/scitranslmed.aau8587.
47. Mizoguchi F, Slowikowski K, Wei K, Marshall JL, Rao DA, Chang SK, Nguyen HN, Noss EH, Turner JD, Earp BE, Blazar PE, Wright J, Simmons BP, Donlin LT, Kalliolias GD, Goodman SM, Bykerk VP, Ivashkiv LB, Lederer JA, Hacohen N, Nigrovic PA, Filer A, Buckley CD, Raychaudhuri S, Brenner MB. Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis. *Nat Commun* 9: 789, 2018. doi:10.1038/s41467-018-02892-y.
48. West NR, Hegazy AN, Owens BMJ, Bullers SJ, Linggi B, Buonocore S, Coccia M, Görtz D, This S, Stockenhuber K, Pott J, Friedrich M, Ryzhakov G, Baribaud F, Brodmerkel C, Cieluch C, Rahman N, Müller-Newen G, Owens RJ, Kühl AA, Maloy KJ, Plevy SE, Keshav S, Travis SPL, Powrie F, Oxford IBD Cohort Investigators. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease. *Nat Med* 23: 579–589, 2017. doi:10.1038/nm.4307.
49. Smillie CS, Biton M, Ordovas-Montanes J, Sullivan KM, Burgin G, Graham DB, Herbst RH, Rogel N, Slyper M, Waldman J, Sud M, Andrews E, Velonias G, Haber AL, Jagadeesh K, Vickovic S, Yao J, Stevens C, Dionne D, Nguyen LT, Villani AC, Hofree M, Creasey EA, Huang H, Rozenblatt-Rosen O, Garber JJ, Khalili H, Desch AN, Daly MJ, Ananthakrishnan AN, Shalek AK, Xavier RJ, Regev A. Intra- and inter-cellular rewiring of the human colon during ulcerative colitis. *Cell* 178: 714–730.e722, 2019. doi:10.1016/j.cell.2019.06.029.
50. Martin JC, Chang C, Boschetti G, Ungaro R, Giri M, Grout JA, Grout JA, Guttler K, Chuang LS, Nayar S, Greenstein AJ, Dubinsky M, Walker L, Leader A, Fine JS, Whitehurst CE, Mbow ML, Kugathasan S, Denson LA, Hyams JS, Friedman JR, Desai PT, Ko HM, Laface I, Akturk G, Schadt EE, Salmon H, Gnajatic S, Rahman AH, Merad M, Cho JH, Kenigsberg E. Single-cell analysis of Crohn's disease lesions identifies a pathogenic cellular module associated with resistance to Anti-TNF therapy. *Cell* 178: 1493–1508.e1420, 2019. doi:10.1016/j.cell.2019.08.008.
51. Smolgovsky S, Ibeh U, Tamayo TP, Alcaide P. Adding insult to injury - Inflammation at the heart of cardiac fibrosis. *Cell Signal* 77: 109828, 2021. doi:10.1016/j.celsig.2020.109828.
52. Ngwenyama N, Salvador AM, Velázquez F, Nevers T, Levy A, Aronovitz M, Luster AD, Huggins GS, Alcaide P. CXCR3 regulates CD4⁺ T cell cardiomyopathy in pressure overload-induced cardiac dysfunction. *JCI Insight* 4: e125527, 2019. doi:10.1172/jci.insight.125527.
53. Liu X, Yin K, Chen L, Chen W, Li W, Zhang T, Sun Y, Yuan M, Wang H, Song Y, Wang S, Hu S, Zhou Z. Lineage-specific regulatory changes in hypertrophic cardiomyopathy unraveled by single-nucleus RNA-seq and spatial transcriptomics. *Cell Discov* 9: 6, 2023. doi:10.1038/s41421-022-00490-3.
54. Kambayashi T, Laufer TM. Atypical MHC class II-expressing antigen-presenting cells: can anything replace a dendritic cell? *Nat Rev Immunol* 14: 719–730, 2014. doi:10.1038/nri3754.
55. Carmona-Rivera C, Carlucci PM, Moore E, Lingampalli N, Uchtenhagen H, James E, Liu YD, Bicker KL, Wahamaa H, Hoffmann V, Catrina AJ, Thompson PR, Buckner JH, Robinson WH, Fox DA, Kaplan MJ. Synovial fibroblast-neutrophil interactions promote pathogenic adaptive immunity in rheumatoid arthritis. *Sci Immunol* 2: eaag3358, 2017 [Erratum in *Sci Immunol* 5: eaaz9319, 2020]. doi:10.1126/sciimmunol.aag3358.
56. Kinchen J, Chen HH, Parikh K, Antanaviciute A, Jagielowicz M, Fawcner-Corbett D, Ashley N, Cubitt L, Mellado-Gomez E, Attar M, Sharma E, Wills Q, Bowden R, Richter FC, Ahern D, Puri KD, Henault J, Gervais F, Koohy H, Simmons A. Structural remodeling of the human colonic mesenchyme in inflammatory bowel disease. *Cell* 175: 372–386.e17, 2018. doi:10.1016/j.cell.2018.08.067.
57. Kerdidani D, Aerakis E, Verrou K-M, Angelidis I, Douka K, Maniou M-A, Stamoulis P, Goudevenou K, Prados A, Tzaferis C, Ntakis V, Vamvakaris I, Kaniaris E, Vachlas K, Sepsas E, Koutsopoulos A, Potaris K, Tsoumakidou M. Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts. *J Exp Med* 219: e20210815, 2022. doi:10.1084/jem.20210815.
58. Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhart RA, Teinor JA, Belleau P, Biffi G, Lucito MS, Sivajothi S, Armstrong TD, Engle DD, Yu KH, Hao Y, Wolfgang CL, Park Y, Preall J, Jaffee EM, Califano A, Robson P, Tuveson DA. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. *Cancer Discov* 9: 1102–1123, 2019. doi:10.1158/2159-8290.CD-19-0094.
59. Ngwenyama N, Kirabo A, Aronovitz M, Velázquez F, Carrillo-Salinas F, Salvador AM, Nevers T, Amarnath V, Tai A, Blanton RM, Harrison DG, Alcaide P. Isolevuglandin-modified cardiac proteins drive CD4⁺ T-cell activation in the heart and promote cardiac dysfunction. *Circulation* 143: 1242–1255, 2021 [Erratum in *Circulation* 143: e794, 2021]. doi:10.1161/CIRCULATIONAHA.120.051889.
60. Ngwenyama N, Kaur K, Bugg D, Theall B, Aronovitz M, Berland R, Panagiotidou S, Genco C, Perrin MA, Davis J, Alcaide P. Antigen presentation by cardiac fibroblasts promotes cardiac dysfunction. *Nat Cardiovasc Res* 1: 761–774, 2022. doi:10.1038/s44161-022-00116-7.
61. Wang L, Yu P, Zhou B, Song J, Li Z, Zhang M, Guo G, Wang Y, Chen X, Han L, Hu S. Single-cell reconstruction of the adult human heart during heart failure and recovery reveals the cellular landscape underlying cardiac function. *Nat Cell Biol* 22: 108–119, 2020. doi:10.1038/s41556-019-0446-7.
62. McNair BD, Shorthill SK, Bruns DR. More than just a small left ventricle: the right ventricular fibroblast and ECM in health and disease. *Am J Physiol Heart Circ Physiol* 325: H385–H397, 2023. doi:10.1152/ajpheart.00213.2023.
63. Gulati A, Japp AG, Raza S, Halliday BP, Jones DA, Newsome S, Ismail NA, Morarji K, Khwaja J, Spath N, Shakespeare C, Kalra PR, Lloyd G, Mathur A, Cleland JGF, Cowie MR, Assomull RG, Pennell DJ, Ismail TF, Prasad SK. Absence of myocardial fibrosis predicts favorable long-term survival in new-onset heart failure. *Circ Cardiovasc Imaging* 11: e007722, 2018. doi:10.1161/CIRCIMAGING.118.007722.
64. Simonson B, Chaffin M, Hill MC, Atwa O, Guedira Y, Bhasin H, Hall AW, Hayat S, Baumgart S, Bedi KC, Margulies KB, Klattenhoff CA, Ellinor PT. Single-nucleus RNA sequencing in ischemic cardiomyopathy reveals common transcriptional profile underlying end-stage heart failure. *Cell Rep* 42: 112086, 2023. doi:10.1016/j.celrep.2023.112086.
65. Chaffin M, Papangelis I, Simonson B, Akkad A-D, Hill MC, Arduini A, Fleming SJ, Melanson M, Hayat S, Kost-Alimova M, Atwa O, Ye J, Bedi KC, Nahrendorf M, Kaushik VK, Stegmann CM, Margulies KB, Tucker NR, Ellinor PT. Single-nucleus profiling of human dilated and hypertrophic cardiomyopathy. *Nature* 608: 174–180, 2022. doi:10.1038/s41586-022-04817-8.
66. Fu X, Khalil H, Kanisicak O, Boyer JG, Vagnozzi RJ, Maliken BD, Sargent MA, Prasad V, Valiente-Alandi I, Blaxall BC, Molkentin JD. Specialized fibroblast differentiated states underlie scar formation in the infarcted mouse heart. *J Clin Invest* 128: 2127–2143, 2018. doi:10.1172/JCI98215.
67. McLellan MA, Skelly DA, Dona MSI, Squiers GT, Farrugia GE, Gaynor TL, Cohen CD, Pandey R, Diep H, Vinh A, Rosenthal NA, Pinto AR. High-resolution transcriptomic profiling of the heart during chronic stress reveals cellular drivers of cardiac fibrosis and hypertrophy. *Circulation* 142: 1448–1463, 2020. doi:10.1161/CIRCULATIONAHA.119.045115.
68. Peisker F, Halder M, Nagai J, Ziegler S, Kaesler N, Hoeft K, Li R, Bindels EMJ, Kuppe C, Moellmann J, Lehrke M, Stoppe C, Schaub MT, Schneider RK, Costa I, Kramann R. Mapping the cardiac vascular niche in heart failure. *Nat Commun* 13: 3027, 2022. doi:10.1038/s41467-022-30682-0.
69. Meyer K, Hodwin B, Ramanujam D, Engelhardt S, Sarikas A. Essential role for premature senescence of myofibroblasts in myocardial fibrosis. *J Am Coll Cardiol* 67: 2018–2028, 2016. doi:10.1016/j.jacc.2016.02.047.
70. Bugg D, Bailey LRJ, Bretherton RC, Beach KE, Reichardt IM, Robeson KZ, Reese AC, Gunaje J, Flint G, DeForest CA, Stempien-Otero A, Davis J. MBNL1 drives dynamic transitions between fibroblasts and myofibroblasts in cardiac wound healing. *Cell Stem Cell* 29: 419–433.e10, 2022. doi:10.1016/j.stem.2022.01.012.
71. Li Y, Li C, Liu Q, Wang L, Bao AX, Jung JP, Dodlapati S, Sun J, Gao P, Zhang X, Francis J, Molkentin JD, Fu X. Loss of Acta2 in cardiac fibroblasts does not prevent the myofibroblast differentiation or

71. affect the cardiac repair after myocardial infarction. *J Mol Cell Cardiol* 171: 117–132, 2022. doi:10.1016/j.jmcc.2022.08.003.
72. Subbaiah KCV, Wu J, Tang WHW, Yao P. FAM114A1 influences cardiac pathological remodeling by regulating angiotensin II signaling. *JCI Insight* 7: e152783, 2022. doi:10.1172/jci.insight.152783.
73. Bayer AL, Smolgovsky S, Ngwenyama N, Hernandez-Martinez A, Kaur K, Sulka K, Amrute J, Aronovitz M, Lavine K, Sharma S, Alcaide P. T-Cell MyD88 is a novel regulator of cardiac fibrosis through modulation of T-cell activation. *Circ Res* 133: 412–429, 2023. doi:10.1161/CIRCRESAHA.123.323030.
74. Huang C, Sharma A, Thakur R, Rai D, Katiki M, Germano JF, Song Y, Singh S, Sin J, Sengstock D, Andres AM, Murali R, Mentzer RM Jr, Gottlieb RA, Piplani H. Asporin, an extracellular matrix protein, is a beneficial regulator of cardiac remodeling. *Matrix Biol* 110: 40–59, 2022. doi:10.1016/j.matbio.2022.04.005.
75. Dupont S, Morsut L, Aragona M, Enzo E, Giullitti S, Cordenonsi M, Zanconato F, Le Digabel J, Forcato M, Bicciato S, Elvassore N, Piccolo S. Role of YAP/TAZ in mechanotransduction. *Nature* 474: 179–183, 2011. doi:10.1038/nature10137.
76. Xiao Y, Hill MC, Li L, Deshmukh V, Martin TJ, Wang J, Martin JF. Hippo pathway deletion in adult resting cardiac fibroblasts initiates a cell state transition with spontaneous and self-sustaining fibrosis. *Genes Dev* 33: 1491–1505, 2019. doi:10.1101/gad.329763.119.
77. Garoffolo G, Casaburo M, Amadeo F, Salvi M, Bernava G, Piacentini L, Chimenti I, Zaccagnini G, Milcovich G, Zuccolo E, Agrifoglio M, Ragazzini S, Baasansuren O, Cozzolino C, Chiesa M, Ferrari S, Carbonaro D, Santoro R, Manzoni M, Casalis L, Raucci A, Molinari F, Menicanti L, Pagano F, Ohashi T, Martelli F, Massai D, Colombo GI, Messina E, Morbiducci U, Pesce M. Reduction of cardiac fibrosis by interference with YAP-dependent transactivation. *Circ Res* 131: 239–257, 2022. doi:10.1161/CIRCRESAHA.121.319373.
78. Mia MM, Cibi DM, Ghani S, Singh A, Tee N, Sivakumar V, Bögireddi H, Cook SA, Mao J, Singh MK. Loss of Yap/Taz in cardiac fibroblasts attenuates adverse remodeling and improves cardiac function. *Cardiovasc Res* 118: 1785–1804, 2022. doi:10.1093/cvr/cvab205.
79. Francisco J, Guan J, Zhang Y, Nakada Y, Mareedu S, Sung E, Hu CM, Oka S, Zhai P, Sadoshima J, Del Re DP. Suppression of myeloid YAP antagonizes adverse cardiac remodeling during pressure overload stress. *J Mol Cell Cardiol* 181: 1–14, 2023. doi:10.1016/j.jmcc.2023.05.004.
80. Kumar V, Prabhu SD, Bansal SS. CD4(+) T-lymphocytes exhibit biphasic kinetics post-myocardial infarction. *Front Cardiovasc Med* 9: 992653, 2022. doi:10.3389/fcvm.2022.992653.
81. Ruiz-Villalba A, Romero JP, Hernandez S, Vilas-Bornoza A, Fortelny N, Castro-Labrador L, San Martín-Uriz P, Lorenzo-Vivas E, García-Olloqui P, Palacio M, Gavira JJ, Bastarrika G, Janssens S, Wu M, Iglesias E, Abizanda G, de Morentin XM, Lasaga M, Planell N, Bock C, Alignedani D, Medal G, Prudovsky I, Jin YR, Ryzhov S, Yin H, Pelacho B, Gomez-Cabrero D, Lindner V, Lara-Astiaso D, Prósper F. Single-cell RNA sequencing analysis reveals a crucial role for CTHRC1 (collagen triple helix repeat containing 1) cardiac fibroblasts after myocardial infarction. *Circulation* 142: 1831–1847, 2020. doi:10.1161/CIRCULATIONAHA.119.044557.
82. Ledoult E, Jendoubi M, Collet A, Guerrier T, Largy A, Specia S, Vivier S, Bray F, Figeac M, Hachulla E, Labalette M, Lepêtre F, Sebda S, Sanges S, Rolando C, Sobanski V, Dubucquoi S, Launay D. Simple gene signature to assess murine fibroblast polarization. *Sci Rep* 12: 11748, 2022. doi:10.1038/s41598-022-15640-6.
83. Saxena A, Dobaczewski M, Rai V, Haque Z, Chen W, Li N, Frangogiannis NG. Regulatory T cells are recruited in the infarcted mouse myocardium and may modulate fibroblast phenotype and function. *Am J Physiol Heart Circ Physiol* 307: H1233–H1242, 2014. doi:10.1152/ajpheart.00328.2014.
84. Han M, Liu Z, Liu L, Huang X, Wang H, Pu W, Wang E, Liu X, Li Y, He L, Li X, Wu J, Qiu L, Shen R, Wang Q-D, Ji Y, Ardehali R, Shu Q, Lui KO, Wang L, Zhou B. Dual genetic tracing reveals a unique fibroblast subpopulation modulating cardiac fibrosis. *Nat Genet* 55: 665–678, 2023. doi:10.1038/s41588-023-01337-7.
85. Chavkin NW, Sano S, Wang Y, Oshima K, Ogawa H, Horitani K, Sano M, MacLauchlan S, Nelson A, Setia K, Vippa T, Watanabe Y, Saucerman JJ, Hirschi KK, Gokce N, Walsh K. The cell surface receptors Ror1/2 control cardiac myofibroblast differentiation. *J Am Heart Assoc* 10: e019904, 2021. doi:10.1161/JAHA.120.019904.
86. Haryono A, Ikeda K, Nugroho DB, Ogata T, Tsuji Y, Matoba S, Moriaki K, Kitagawa H, Igarashi M, Hirata KI, Emoto N. ChGn-2 plays a cardioprotective role in heart failure caused by acute pressure overload. *J Am Heart Assoc* 11: e023401, 2022. doi:10.1161/JAHA.121.023401.
87. Burke RM, Dirks RA Jr, Quijada P, Lighthouse JK, Mohan A, O'Brien M, Wojciechowski W, Woeller CF, Phipps RP, Alexis JD, Ashton JM, Small EM. Prevention of fibrosis and pathological cardiac remodeling by Salinomycin. *Circ Res* 128: 1663–1678, 2021. doi:10.1161/CIRCRESAHA.120.317791.
88. Tsao CW, Aday AW, Almarazooq ZI, Anderson CAM, Arora P, Avery CL et al. Heart Disease and Stroke Statistics-2023 Update: a report from the American Heart Association. *Circulation* 147: e93–e621, 2023 [Erratum in *Circulation* 147: e622, 2023, and in *Circulation* 148: e4, 2023]. doi:10.1161/CIR.0000000000001123.
89. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. *N Engl J Med* 381: 1609–1620, 2019. doi:10.1056/NEJMoa1908655.
90. Zhang W, Liu J, Fu Y, Ji H, Fang Z, Zhou W, Fan H, Zhang Y, Liao Y, Yang T, Wang X, Yuan W, Chen X, Dong YF. Sacubitril/valsartan reduces fibrosis and alleviates high-salt diet-induced HFpEF in rats. *Front Pharmacol* 11: 600953, 2020. doi:10.3389/fphar.2020.600953.
91. Schiattarella GG, Alcaide P, Condorelli G, Gillette TG, Heymans S, Jones EAV, Kallikourdis M, Lichtman A, Marelli-Berg F, Shah S, Thorp EB, Hill JA. Immunometabolic mechanisms of heart failure with preserved ejection fraction. *Nat Cardiovasc Res* 1: 211–222, 2022. doi:10.1038/s44161-022-00032-w.
92. Haaf P, Garg P, Messroghli DR, Broadbent DA, Greenwood JP, Plein S. Cardiac T1 mapping and extracellular volume (ECV) in clinical practice: a comprehensive review. *J Cardiovasc Magn Reson* 18: 89, 2016. doi:10.1186/s12968-016-0308-4.
93. Kanagala P, Cheng ASH, Singh A, Khan JN, Gulsin GS, Patel P, Gupta P, Arnold JR, Squire IB, Ng LL, McCann GP. Relationship between focal and diffuse fibrosis assessed by CMR and clinical outcomes in heart failure with preserved ejection fraction. *JACC Cardiovasc Imaging* 12: 2291–2301, 2019. doi:10.1016/j.jcmg.2018.11.031.
94. Westermann D, Lindner D, Kasner M, Zietsch C, Savvatis K, Escher F, von Schlippenbach J, Skurk C, Steendijk P, Riad A, Poller W, Schultheiss HP, Tschöpe C. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. *Circ Heart Fail* 4: 44–52, 2011. doi:10.1161/CIRCHEARTFAILURE.109.931451.
95. Hahn VS, Yanek LR, Vaishnav J, Ying W, Vaidya D, Lee YZJ, Riley SJ, Subramanya V, Brown EE, Hopkins CD, Ononogbu S, Perzel Mandell K, Halushka MK, Steenbergen C Jr, Rosenberg AZ, Tedford RJ, Judge DP, Shah SJ, Russell SD, Kass DA, Sharma K. Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis. *JACC Heart Fail* 8: 712–724, 2020. doi:10.1016/j.jchf.2020.04.007.
96. Mohammed SF, Mirzoyev SA, Edward WD, Dogan A, Grogan DR, Dunlay SM, Roger VL, Gertz MA, Dispenzieri A, Zeldenrust SR, Redfield MM. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. *JACC Heart Fail* 2: 113–122, 2014. doi:10.1016/j.jchf.2013.11.004.
97. Lewis GA, Dodd S, Clayton D, Bedson E, Eccleson H, Schelbert EB, Naip JH, Jimenez BD, Williams SG, Cunningham C, Ahmed FZ, Cooper A, Rajavarma V, Russell S, McDonagh T, Williamson PR, Miller CA. Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial. *Nat Med* 27: 1477–1482, 2021. doi:10.1038/s41591-021-01452-0.
98. Hahn VS, Knutsdottir H, Luo X, Bedi K, Margulies KB, Haldar SM, Stolina M, Yin J, Khakoo AY, Vaishnav J, Bader JS, Kass DA, Sharma K. Myocardial gene expression signatures in human heart failure with preserved ejection fraction. *Circulation* 143: 120–134, 2021 [Erratum in *Circulation* 143: e1027, 2021]. doi:10.1161/CIRCULATIONAHA.120.050498.
99. Zhang XL, Wang TY, Chen Z, Wang HW, Yin Y, Wang L, Wang Y, Xu B, Xu W. HMGB1-promoted neutrophil extracellular traps contribute to cardiac diastolic dysfunction in mice. *J Am Heart Assoc* 11: e023800, 2022. doi:10.1161/JAHA.121.023800.
100. Deng Y, Xie M, Li Q, Xu X, Ou W, Zhang Y, Xiao H, Yu H, Zheng Y, Liang Y, Jiang C, Chen G, Du D, Zheng W, Wang S, Gong M, Chen Y, Tian R, Li T. Targeting mitochondria-inflammation circuit by

- β -hydroxybutyrate mitigates HFpEF. *Circ Res* 128: 232–245, 2021 [Erratum in *Circ Res* 130: e24, 2022]. doi:[10.1161/CIRCRESAHA.120.317933](https://doi.org/10.1161/CIRCRESAHA.120.317933).
101. Li Y, Kubo H, Yu D, Yang Y, Johnson JP, Eaton DM, Berretta RM, Foster M, McKinsey TA, Yu J, Elrod JW, Chen X, Houser SR. Combining three independent pathological stressors induces a heart failure with preserved ejection fraction phenotype. *Am J Physiol Heart Circ Physiol* 324: H443–H460, 2023. doi:[10.1152/ajpheart.00594.2022](https://doi.org/10.1152/ajpheart.00594.2022).
 102. Travers JG, Wennersten SA, Peña B, Bagchi RA, Smith HE, Hirsch RA, Vanderlinden LA, Lin YH, Dobrinskikh E, Demos-Davies KM, Cavasin MA, Mestroni L, Steinkühler C, Lin CY, Houser SR, Woulfe KC, Lam MPY, McKinsey TA. HDAC inhibition reverses preexisting diastolic dysfunction and blocks covert extracellular matrix remodeling. *Circulation* 143: 1874–1890, 2021. doi:[10.1161/CIRCULATIONAHA.120.046462](https://doi.org/10.1161/CIRCULATIONAHA.120.046462).
 103. Valero-Muñoz M, Oh A, Faudoa E, Bretón-Romero R, El Adili F, Bujor A, Sam F. Endothelial-mesenchymal transition in heart failure with a preserved ejection fraction: insights into the cardiorenal syndrome. *Circ Heart Fail* 14: e008372, 2021. doi:[10.1161/CIRCHEARTFAILURE.121.008372](https://doi.org/10.1161/CIRCHEARTFAILURE.121.008372).
 104. Elkholey K, Niewiadomska M, Morris L, Whyte S, Houser J, Humphrey MB, Stavrakis S. Transcutaneous vagus nerve stimulation ameliorates the phenotype of heart failure with preserved ejection fraction through its anti-inflammatory effects. *Circ Heart Fail* 15: e009288, 2022. doi:[10.1161/CIRCHEARTFAILURE.122.009288](https://doi.org/10.1161/CIRCHEARTFAILURE.122.009288).
 105. Gerdtz E, Regitz-Zagrosek V. Sex differences in cardiometabolic disorders. *Nat Med* 25: 1657–1666, 2019. doi:[10.1038/s41591-019-0643-8](https://doi.org/10.1038/s41591-019-0643-8).
 106. Angelini A, Ortiz-Urbina J, Trial J, Reddy AK, Malovannaya A, Jain A, Entman ML, Taffet GE, Cieslik KA. Sex-specific phenotypes in the aging mouse heart and consequences for chronic fibrosis. *Am J Physiol Heart Circ Physiol* 323: H285–H300, 2022. doi:[10.1152/ajpheart.00078.2022](https://doi.org/10.1152/ajpheart.00078.2022).
 107. Lam CSP, Arnott C, Beale AL, Chandramouli C, Hilfiker-Kleiner D, Kaye DM, Ky B, Santema BT, Sliwa K, Voors AA. Sex differences in heart failure. *Eur Heart J* 40: 3859–3868c, 2019. doi:[10.1093/eurheartj/ehz835](https://doi.org/10.1093/eurheartj/ehz835).